Abstract
GEN EdgeVol. 3, No. 1 Genome EditingBeleaguered Bluebird's New CEO Charts Comeback Course with “Zero Distractions”Following the spin-off of Bluebird's oncology programs into 2Seventy bio, Bluebird CEO Andrew Obenshain addresses his company's focus on severe genetic disease and his steadfast belief in lentiviral vectorsAlex PhilippidisAlex PhilippidisSearch for more papers by this authorPublished Online:15 Nov 2021https://doi.org/10.1089/genedge.3.1.112AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 3Issue 1Jan 2021 Information© 2021 by GEN PublishingTo cite this article:Alex Philippidis.Beleaguered Bluebird's New CEO Charts Comeback Course with “Zero Distractions”.GEN Edge.Jan 2021.673-680.http://doi.org/10.1089/genedge.3.1.112Published in Volume: 3 Issue 1: November 15, 2021PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
